Literature DB >> 26478010

Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.

Sangmoon Lee1, Jin Soo Moon2, Cho-Rong Lee3, Hye-Eun Kim3, Sun-Mi Baek3, Solha Hwang2, Gyeong Hoon Kang4, Jeong Kee Seo2, Choong Ho Shin2, Hyoung Jin Kang5, Jae Sung Ko6, Sung Gyoo Park7, Murim Choi8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26478010     DOI： 10.1016/j.jaci.2015.08.036

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  50 in total

1.  Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.

Authors:  Ester M van Leeuwen; Eloy Cuadrado; Anke M Gerrits; Esther Witteveen; Godelieve J de Bree
Journal:  J Clin Immunol       Date:  2018-05-23       Impact factor: 8.317

Review 2.  T Regulatory Cell Biology in Health and Disease.

Authors:  Fayhan J Alroqi; Talal A Chatila
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

3.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

Review 4.  CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.

Authors:  Bernice Lo; Jill M Fritz; Helen C Su; Gulbu Uzel; Michael B Jordan; Michael J Lenardo
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

Review 5.  Unintended Immunological Consequences of Biologic Therapy.

Authors:  Sarah E Henrickson; Melanie A Ruffner; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 6.  Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.

Authors:  Luigi D Notarangelo; Thomas A Fleisher
Journal:  J Allergy Clin Immunol       Date:  2017-03       Impact factor: 10.793

Review 7.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 8.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

Review 9.  Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies.

Authors:  Ottavia Maria Delmonte; Luigi Daniele Notarangelo
Journal:  Med Princ Pract       Date:  2019-10-10       Impact factor: 1.927

Review 10.  Primary B-cell immunodeficiencies.

Authors:  Tukisa Smith; Charlotte Cunningham-Rundles
Journal:  Hum Immunol       Date:  2018-10-22       Impact factor: 2.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.